Philip C Amrein
Overview
Explore the profile of Philip C Amrein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amrein P, Preffer F, Fell G, Attar E, Narayan R, Blonquist T, et al.
Leuk Lymphoma
. 2025 Mar;
:1-11.
PMID: 40070233
Outcome for acute myeloid leukemia (AML) patients aged >60 years is poor. Targeting the proteasome in AML is attractive, since leukemia stem cells demonstrate sensitivity to proteasome inhibition in preclinical...
2.
Fathi A, Kim H, Soiffer R, Levis M, Li S, Kim A, et al.
Clin Cancer Res
. 2023 Apr;
29(11):2034-2042.
PMID: 37014667
Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use in patients with IDH1-mutated...
3.
Nardi V, McAfee S, Dal Cin P, Tsai H, Amrein P, Hobbs G, et al.
Oncologist
. 2022 May;
27(2):82-86.
PMID: 35641210
BCR-ABL1 kinase inhibitors have improved the prognosis of Philadelphia-chromosome-positive (Ph+)-acute lymphoblastic leukemia (ALL). Ph-like (or BCR-ABL1-like) ALL does not express BCR-ABL1 but commonly harbors other genomic alterations of signaling molecules...
4.
Woo S, Wu M, Treister N, Amrein P, Kroshinsky D, Hasserjian R
N Engl J Med
. 2021 Oct;
385(18):1700-1710.
PMID: 34706175
No abstract available.
5.
Signorelli J, Lei M, Lam J, Jalbut M, Amrein P, Fathi A, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Sep;
20(11):e883-e889.
PMID: 32917574
Background: Antifungal prophylaxis during induction for acute myeloid leukemia (AML) varies according to local rates of invasive fungal infections (IFIs). We evaluated fluconazole prophylaxis and no antifungal prophylaxis, as a...
6.
Venkataraman V, Casey K, Onozato M, Dal Cin P, Nardi V, Amrein P, et al.
Leukemia
. 2020 Jul;
34(11):3050-3054.
PMID: 32678290
No abstract available.
7.
Nardi V, Ku N, Frigault M, Dubuc A, Tsai H, Amrein P, et al.
Blood Adv
. 2020 Jan;
4(1):106-111.
PMID: 31905241
Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a subtype of Ph-negative ALL that molecularly resembles Ph-positive ALL. It shares the adverse prognosis of Ph-positive ALL, but lacks the BCR-ABL1...
8.
Narayan R, Blonquist T, Emadi A, Hasserjian R, Burke M, Lescinskas C, et al.
Cancer
. 2019 Dec;
126(6):1264-1273.
PMID: 31860140
Background: Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that...
9.
Brunner A, Blonquist T, DeAngelo D, McMasters M, Fell G, Hermance N, et al.
Lancet Haematol
. 2019 Dec;
7(2):e122-e133.
PMID: 31837959
Background: Increased aurora A kinase (AAK) expression occurs in acute myeloid leukaemia; AAK inhibition is a promising therapeutic target in this disease. We therefore aimed to assess the activity of...
10.
Slavin S, Fenech A, Jankowski A, Abel G, Brunner A, Steensma D, et al.
Cancer
. 2019 Jul;
125(21):3845-3852.
PMID: 31299106
Background: Older adults with acute myeloid leukemia (AML) are often assumed to have poor outcomes after admission to the intensive care unit (ICU). However, little is known about ICU utilization...